[On-site negotiation and bidding for the 2026 National Medical Insurance Catalog and price negotiation for the commercially insured innovative drug catalog begin in Beijing] On September 5, the negotiation and bidding for the 2026 National Basic Medical Insurance Drug Catalog and the price negotiation for the commercially insured innovative drug catalog officially opened today at the National People's Congress Conference Center in Beijing. Reporters observed at the scene that around 7:30 in the morning, corporate negotiators had arrived at the scene and were waiting. It is worth noting that this year’s national talks have further strengthened pre-negotiation communication, and new mechanisms such as drug pre-communication and pre-declaration have been gradually implemented, and the time node for enterprises to deploy medical insurance has continued to move forward. The National Medical Insurance Administration previously disclosed that there were 664 drug generic name applications for the 2026 adjustment of the basic medical insurance catalog, and 601 ultimately passed the formal review; there were 62 drug generic name applications for the commercially insured innovative drug catalog, and 58 passed the formal review. Many local innovative drug rising stars and leading companies such as Bailey Tianheng, Keji Pharmaceutical, BeiGene, Sansheng Guojian, Zhixiang Jintai, etc. have applied. The industry expects that the current round of on-site negotiation and bidding for the adjustment of the national medical insurance catalog and the price negotiation of the commercially insured innovative drug catalog will last 4 to 5 days. (Reporters Lu Afeng and Yu Miao)